Table 1.
Name | Structure | CarD-BODIPY-FL assay | CarD-DAOTA assay | ||
---|---|---|---|---|---|
CCG sample IC50 (µM) | Powder sample IC50 (µM) | CCG sample IC50 (µM) | Powder sample IC50 (µM) | ||
CCG-237488 | 25 | ND | 20 | ND | |
CCG-249580 | 263 | 202 | 32 | 45 | |
019–738-824 | N/A | > 100* | N/A | > 100 | |
008–371-831 | N/A | > 100 | N/A | > 100 | |
046–418-303 (Ridinilazole) | N/A | > 100 | N/A | > 100 |
N/A: not applicable, compounds were not in CCG library. N/D: not determined.
*Compounds were inactive up to 100 µM. They exhibited inhibition above 100 µM which is likely artifactual due to compound aggregation.